To the Editor In a prespecified analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM III) trial, Goldstein et al1 demonstrated that the superior treatment effect of the HeartMate 3 over HeartMate II was similar regardless of current or future transplant eligibility and that clinical dispositions were dynamic. The authors proposed abandoning discrete transplant eligibility labels in favor of a single preimplant strategy.1 Could there be value in translating the success achieved by the use of the more hemocompatible HeartMate 3 system to refine rather than unify the implant strategy? The paradigm of value-based care and myocardial recovery may favor the former approach.
Mehmood M. Redefining Left Ventricular Assist Device Indications and Strategies. JAMA Cardiol. 2021;6(1):119–120. doi:10.1001/jamacardio.2020.4320
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: